New CRISPR technique turns cancer’s own mutations into a self-destruct signal
A team of researchers led by Nobel laureate Jennifer Doudna has demonstrated a new approach to cancer treatment that uses the cell’s own mutation signature as a homing beacon for self-destruction. The technique, published in Nature on June 8, targets cancer cells carrying p53 tumor suppressor mutations — a category of cancer so resistant to conventional drugs that it has been considered “undruggable” for decades (Nature; Innovative Genomics Institute).
p53 is the most commonly mutated gene in cancer, appearing in roughly 40 to 50% of all human cancers. In ovarian, pancreatic, and non-small cell lung cancers, the rate can reach 70 to 90%. Yet no approved therapy has ever successfully targeted mutant p53 — the protein lacks the binding pockets that conventional small-molecule drugs need to latch onto, and the mutations are loss-of-function, meaning the standard drug paradigm of inhibiting a hyperactive protein does not apply.
The CRISPR approach bypasses the protein entirely.
How it works
The system uses Cas12a2, a type V CRISPR nuclease first characterized by researchers at Utah State University in a foundational Nature paper published May 6 (Nature). In nature, Cas12a2 acts as a bacterial defense mechanism: when it detects a matching RNA target indicating viral infection, it destroys all genetic material in the cell to stop the virus from spreading.
The Doudna lab reprogrammed Cas12a2’s guide RNA to recognize the specific RNA transcript produced only by cells carrying a mutated p53 gene. When the guide RNA finds its target inside a cancer cell, Cas12a2 activates and begins indiscriminately cleaving double-stranded DNA across the entire genome — a process the researchers describe as “chromatin shredding.” The widespread genetic damage triggers catastrophic cell death, while healthy cells lacking the mutant RNA signature are left untouched.
The researchers demonstrated the technique in mouse models of lung and liver tumors. First author Jingkun Zeng, a postdoctoral researcher at the Innovative Genomics Institute and Gladstone Institutes, completed the work with collaborators from UC Berkeley, UC San Francisco, the University of Utah, and the Francis Crick Institute.
What ‘undruggable’ actually means
The term has a specific meaning in oncology. Unlike oncogenes (genes that promote cancer when hyperactive), tumor suppressor genes like p53 prevent cancer when functioning normally. When p53 mutates, it loses that protective function. Traditional drug discovery tries to restore lost function, which is much harder than blocking a hyperactive target.
After 40 years of failed attempts to drug p53 directly, the CRISPR approach represents a fundamentally different strategy. Instead of trying to fix the broken protein, it uses the broken protein’s genetic signature as a trigger to eliminate the cell entirely.
Delivery and timeline
The Nature paper is a proof-of-concept in animal models. Clinical translation would require solving the delivery problem: getting the CRISPR components into the right cells in the human body, at scale, without triggering immune responses. The researchers noted that lipid nanoparticle delivery systems, similar to those used in mRNA COVID-19 vaccines, are a plausible path forward, but human trials remain years away.
Still, the approach is conceptually generalizable. The same system could theoretically be programmed to recognize any cancer-specific RNA transcript, not just p53 mutations. If delivery challenges can be solved, the technique offers a way to target cancer types that have resisted every other therapeutic approach.
Sources: Nature (June 8, 2026); Innovative Genomics Institute (June 8, 2026); Nature (foundational) (May 6, 2026); UCSF (June 8, 2026); GEN News (June 8, 2026)